{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T16:33:45Z","timestamp":1785170025714,"version":"3.55.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T00:00:00Z","timestamp":1682294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T00:00:00Z","timestamp":1682294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This study reported the short-term effects of intravitreal brolucizumab (IVB) on peripapillary retinal nerve fiber layer (RNFL) thickness in patients with neovascular age-related macular degeneration (nAMD). This retrospective observational case series included patients with nAMD treated with other anti-vascular endothelial growth factor (anti-VEGF) agents and subsequently switched to IVB because of poor response to those other agents on spectral domain optical coherence tomography (SD-OCT). Best-corrected visual acuity (BCVA), intraocular pressure, funduscopy, and SD-OCT were assessed at baseline, 2\u00a0weeks, 1\u00a0month, and 3\u00a0months after injection. Twenty-two patients were included in the study. In the IVB group, BCVA significantly improved 3\u00a0months after injection compared with baseline (0.45\u2009\u00b1\u20090.25 vs. 0.38\u2009\u00b1\u20090.25, <jats:italic>p<\/jats:italic>\u2009=\u20090.012). During the 3-month follow-up, compared with baseline, RNFL thicknesses of the global, superior temporal, inferior temporal, inferior nasal, nasal, and superior nasal sectors did not change substantially in the IVB group. However, temporal RNFL thickness significantly decreased at 1\u00a0month (<jats:italic>p<\/jats:italic>\u2009=\u20090.045), and the significance was lost at 3\u00a0months (<jats:italic>p<\/jats:italic>\u2009=\u20090.378). The central macular thickness of treated eyes significantly decreased compared with the baseline at every follow-up visit. IVB in patients with nAMD had morphological and functional visual gain effects without RNFL thinning during the short-term follow-up.\n<\/jats:p>","DOI":"10.1038\/s41598-023-32024-6","type":"journal-article","created":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T15:03:17Z","timestamp":1682348597000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Short-term effect of intravitreal brolucizumab injections in patients with neovascular age-related macular degeneration on retinal nerve fiber layer thickness"],"prefix":"10.1038","volume":"13","author":[{"given":"Sung Yeon","family":"Jun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Duck-Jin","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,24]]},"reference":[{"key":"32024_CR1","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/S0140-6736(12)60282-7","volume":"379","author":"LS Lim","year":"2012","unstructured":"Lim, L. S., Mitchell, P., Seddon, J. M., Holz, F. G. & Wong, T. Y. Age-related macular degeneration. Lancet 379, 1728\u20131738. https:\/\/doi.org\/10.1016\/S0140-6736(12)60282-7 (2012).","journal-title":"Lancet"},{"key":"32024_CR2","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld, P. J. et al. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 355, 1419\u20131431. https:\/\/doi.org\/10.1056\/NEJMoa054481 (2006).","journal-title":"N. Engl. J. Med."},{"key":"32024_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ajo.2011.10.016","volume":"153","author":"SB Bloch","year":"2012","unstructured":"Bloch, S. B., Larsen, M. & Munch, I. C. Incidence of legal blindness from age-related macular degeneration in denmark: Year 2000 to 2010. Am. J. Ophthalmol. 153, 209-213 e202. https:\/\/doi.org\/10.1016\/j.ajo.2011.10.016 (2012).","journal-title":"Am. J. Ophthalmol."},{"key":"32024_CR4","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ophtha.2020.06.028","volume":"128","author":"PU Dugel","year":"2021","unstructured":"Dugel, P. U. et al. HAWK and HARRIER: Ninety-six-week outcomes from the phase 3 trials of Brolucizumab for neovascular age-related macular degeneration. Ophthalmology 128, 89\u201399. https:\/\/doi.org\/10.1016\/j.ophtha.2020.06.028 (2021).","journal-title":"Ophthalmology"},{"key":"32024_CR5","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/j.ophtha.2017.03.057","volume":"124","author":"PU Dugel","year":"2017","unstructured":"Dugel, P. U. et al. Brolucizumab versus aflibercept in participants with neovascular age-related macular degeneration: A randomized trial. Ophthalmology 124, 1296\u20131304. https:\/\/doi.org\/10.1016\/j.ophtha.2017.03.057 (2017).","journal-title":"Ophthalmology"},{"key":"32024_CR6","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.ophtha.2015.12.030","volume":"123","author":"FG Holz","year":"2016","unstructured":"Holz, F. G. et al. Single-chain antibody fragment VEGF inhibitor RTH258 for neovascular age-related macular degeneration: A randomized controlled study. Ophthalmology 123, 1080\u20131089. https:\/\/doi.org\/10.1016\/j.ophtha.2015.12.030 (2016).","journal-title":"Ophthalmology"},{"key":"32024_CR7","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1177\/2474126420930863","volume":"4","author":"AJ Witkin","year":"2020","unstructured":"Witkin, A. J. et al. Occlusive retinal vasculitis following intravitreal Brolucizumab. J. Vitreoretin. Dis. 4, 269\u2013279. https:\/\/doi.org\/10.1177\/2474126420930863 (2020).","journal-title":"J. Vitreoretin. Dis."},{"key":"32024_CR8","doi-asserted-by":"publisher","first-page":"100687","DOI":"10.1016\/j.ajoc.2020.100687","volume":"18","author":"A Jain","year":"2020","unstructured":"Jain, A. et al. Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolucizumab administrations. Am. J. Ophthalmol. Case Rep. 18, 100687. https:\/\/doi.org\/10.1016\/j.ajoc.2020.100687 (2020).","journal-title":"Am. J. Ophthalmol. Case Rep."},{"key":"32024_CR9","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/j.ophtha.2020.04.017","volume":"127","author":"CR Baumal","year":"2020","unstructured":"Baumal, C. R. et al. Retinal vasculitis and intraocular inflammation after intravitreal injection of Brolucizumab. Ophthalmology 127, 1345\u20131359. https:\/\/doi.org\/10.1016\/j.ophtha.2020.04.017 (2020).","journal-title":"Ophthalmology"},{"key":"32024_CR10","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.ophtha.2020.11.011","volume":"128","author":"J Mones","year":"2021","unstructured":"Mones, J. et al. Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with Brolucizumab: Post hoc review of HAWK and HARRIER. Ophthalmology 128, 1050\u20131059. https:\/\/doi.org\/10.1016\/j.ophtha.2020.11.011 (2021).","journal-title":"Ophthalmology"},{"key":"32024_CR11","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/s00347-021-01321-8","volume":"118","author":"FG Holz","year":"2021","unstructured":"Holz, F. G., Heinz, C., Wolf, A., Hoerauf, H. & Pleyer, U. Intraocular inflammation with brolucizumab use: Patient management-diagnosis-therapy. Ophthalmologe 118, 248\u2013256. https:\/\/doi.org\/10.1007\/s00347-021-01321-8 (2021).","journal-title":"Ophthalmologe"},{"key":"32024_CR12","doi-asserted-by":"publisher","first-page":"5731","DOI":"10.1523\/JNEUROSCI.19-14-05731.1999","volume":"19","author":"M Sondell","year":"1999","unstructured":"Sondell, M., Lundborg, G. & Kanje, M. Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system. J. Neurosci. 19, 5731\u20135740 (1999).","journal-title":"J. Neurosci."},{"key":"32024_CR13","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2353\/ajpath.2007.061237","volume":"171","author":"K Nishijima","year":"2007","unstructured":"Nishijima, K. et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am. J. Pathol. 171, 53\u201367. https:\/\/doi.org\/10.2353\/ajpath.2007.061237 (2007).","journal-title":"Am. J. Pathol."},{"key":"32024_CR14","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1159\/000088637","volume":"14","author":"I Zachary","year":"2005","unstructured":"Zachary, I. Neuroprotective role of vascular endothelial growth factor: Signalling mechanisms, biological function, and therapeutic potential. Neurosignals 14, 207\u2013221. https:\/\/doi.org\/10.1159\/000088637 (2005).","journal-title":"Neurosignals"},{"key":"32024_CR15","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1097\/IAE.0b013e3180592ba6","volume":"27","author":"IA Falkenstein","year":"2007","unstructured":"Falkenstein, I. A., Cheng, L. & Freeman, W. R. Changes of intraocular pressure after intravitreal injection of bevacizumab (avastin). Retina 27, 1044\u20131047. https:\/\/doi.org\/10.1097\/IAE.0b013e3180592ba6 (2007).","journal-title":"Retina"},{"issue":"930\u2013934","key":"32024_CR16","doi-asserted-by":"publisher","first-page":"e931","DOI":"10.1016\/j.ajo.2008.07.007","volume":"146","author":"JE Kim","year":"2008","unstructured":"Kim, J. E., Mantravadi, A. V., Hur, E. Y. & Covert, D. J. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am. J. Ophthalmol. 146(930\u2013934), e931. https:\/\/doi.org\/10.1016\/j.ajo.2008.07.007 (2008).","journal-title":"Am. J. Ophthalmol."},{"key":"32024_CR17","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1177\/112067211002000124","volume":"20","author":"V Sharei","year":"2010","unstructured":"Sharei, V., Hohn, F., Kohler, T., Hattenbach, L. O. & Mirshahi, A. Course of intraocular pressure after intravitreal injection of 0.05 mL ranibizumab (Lucentis). Eur. J. Ophthalmol. 20, 174\u2013179. https:\/\/doi.org\/10.1177\/112067211002000124 (2010).","journal-title":"Eur. J. Ophthalmol."},{"key":"32024_CR18","doi-asserted-by":"publisher","first-page":"6214","DOI":"10.1167\/iovs.12-9875","volume":"53","author":"JM Martinez-de-la-Casa","year":"2012","unstructured":"Martinez-de-la-Casa, J. M. et al. Retinal nerve fiber layer thickness changes in patients with age-related macular degeneration treated with intravitreal ranibizumab. Invest Ophthalmol. Vis. Sci. 53, 6214\u20136218. https:\/\/doi.org\/10.1167\/iovs.12-9875 (2012).","journal-title":"Invest Ophthalmol. Vis. Sci."},{"key":"32024_CR19","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.oret.2020.10.004","volume":"5","author":"L Wang","year":"2021","unstructured":"Wang, L. et al. Dose-response relationship between intravitreal injections and retinal nerve fiber layer thinning in age-related macular degeneration. Ophthalmol. Retina 5, 648\u2013654. https:\/\/doi.org\/10.1016\/j.oret.2020.10.004 (2021).","journal-title":"Ophthalmol. Retina"},{"issue":"558\u2013561","key":"32024_CR20","doi-asserted-by":"publisher","first-page":"e551","DOI":"10.1016\/j.ajo.2010.04.029","volume":"150","author":"MB Horsley","year":"2010","unstructured":"Horsley, M. B., Mandava, N., Maycotte, M. A. & Kahook, M. Y. Retinal nerve fiber layer thickness in patients receiving chronic anti-vascular endothelial growth factor therapy. Am. J. Ophthalmol. 150(558\u2013561), e551. https:\/\/doi.org\/10.1016\/j.ajo.2010.04.029 (2010).","journal-title":"Am. J. Ophthalmol."},{"key":"32024_CR21","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3980\/j.issn.2222-3959.2013.02.20","volume":"6","author":"G Sobaci","year":"2013","unstructured":"Sobaci, G., Gungor, R. & Ozge, G. Effects of multiple intravitreal anti-VEGF injections on retinal nerve fiber layer and intraocular pressure: A comparative clinical study. Int. J. Ophthalmol. 6, 211\u2013215. https:\/\/doi.org\/10.3980\/j.issn.2222-3959.2013.02.20 (2013).","journal-title":"Int. J. Ophthalmol."},{"key":"32024_CR22","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1167\/iovs.13-13769","volume":"55","author":"HJ Shin","year":"2014","unstructured":"Shin, H. J., Shin, K. C., Chung, H. & Kim, H. C. Change of retinal nerve fiber layer thickness in various retinal diseases treated with multiple intravitreal antivascular endothelial growth factor. Invest. Ophthalmol. Vis. Sci 55, 2403\u20132411. https:\/\/doi.org\/10.1167\/iovs.13-13769 (2014).","journal-title":"Invest. Ophthalmol. Vis. Sci"},{"key":"32024_CR23","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3109\/02713683.2014.917190","volume":"40","author":"S Demirel","year":"2015","unstructured":"Demirel, S., Batioglu, F., Ozmert, E. & Erenler, F. The effect of multiple injections of ranibizumab on retinal nerve fiber layer thickness in patients with age-related macular degeneration. Curr. Eye Res. 40, 87\u201392. https:\/\/doi.org\/10.3109\/02713683.2014.917190 (2015).","journal-title":"Curr. Eye Res."},{"key":"32024_CR24","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1089\/jop.2016.0014","volume":"32","author":"EA Sengul","year":"2016","unstructured":"Sengul, E. A. et al. Retinal nerve fiber layer thickness changes in age-related macular degeneration treated with multiple intravitreal ranibizumab. J. Ocul. Pharmacol. Ther. 32, 665\u2013670. https:\/\/doi.org\/10.1089\/jop.2016.0014 (2016).","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"32024_CR25","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ajo.2022.07.025","volume":"243","author":"SM Shah","year":"2022","unstructured":"Shah, S. M. et al. Risk, prevalence, and progression of glaucoma in eyes with age-related macular degeneration treated with intravitreal anti-vascular endothelial growth factor injections. Am J Ophthalmol 243, 98\u2013108. https:\/\/doi.org\/10.1016\/j.ajo.2022.07.025 (2022).","journal-title":"Am J Ophthalmol"},{"key":"32024_CR26","doi-asserted-by":"publisher","DOI":"10.1111\/aos.15283","author":"Y Abu Dail","year":"2022","unstructured":"Abu Dail, Y., Seitz, B., Sideroudi, H. & Abdin, A. D. Impact of intravitreal ranibizumab, aflibercept and bevacizumab on retinal ganglion cell and nerve fibre layer thickness in Neovascular age-related macular degeneration. Acta Ophthalmol. https:\/\/doi.org\/10.1111\/aos.15283 (2022).","journal-title":"Acta Ophthalmol."},{"key":"32024_CR27","doi-asserted-by":"publisher","first-page":"5010","DOI":"10.1038\/s41598-021-84648-1","volume":"11","author":"J Ahn","year":"2021","unstructured":"Ahn, J., Jang, K., Sohn, J., Park, J. I. & Hwang, D. D. Effect of intravitreal ranibizumab and aflibercept injections on retinal nerve fiber layer thickness. Sci. Rep. 11, 5010. https:\/\/doi.org\/10.1038\/s41598-021-84648-1 (2021).","journal-title":"Sci. Rep."},{"key":"32024_CR28","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","volume":"127","author":"PU Dugel","year":"2020","unstructured":"Dugel, P. U. et al. HAWK and HARRIER: Phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology 127, 72\u201384. https:\/\/doi.org\/10.1016\/j.ophtha.2019.04.017 (2020).","journal-title":"Ophthalmology"},{"key":"32024_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2020-318672","author":"LM Bulirsch","year":"2021","unstructured":"Bulirsch, L. M. et al. Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study. Br. J. Ophthalmol. https:\/\/doi.org\/10.1136\/bjophthalmol-2020-318672 (2021).","journal-title":"Br. J. Ophthalmol."},{"key":"32024_CR30","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1136\/bjophthalmol-2021-319090","volume":"106","author":"Y Ogura","year":"2022","unstructured":"Ogura, Y. et al. Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK. Br. J. Ophthalmol. 106, 994\u2013999. https:\/\/doi.org\/10.1136\/bjophthalmol-2021-319090 (2022).","journal-title":"Br. J. Ophthalmol."},{"key":"32024_CR31","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1097\/IAE.0000000000002762","volume":"40","author":"K Lee","year":"2020","unstructured":"Lee, K., Park, Y. G. & Park, Y. H. Visual prognosis after pneumatic displacement of submacular hemorrhage according to age-related macular degeneration subtypes. Retina 40, 2304\u20132311. https:\/\/doi.org\/10.1097\/IAE.0000000000002762 (2020).","journal-title":"Retina"},{"key":"32024_CR32","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1007\/s00417-020-05028-5","volume":"259","author":"JH Lee","year":"2021","unstructured":"Lee, J. H., Kim, J. H., Kim, J. W., Kim, C. G. & Lee, D. W. Difference in treatment burden of neovascular age-related macular degeneration among different types of neovascularization. Graefes Arch. Clin. Exp. Ophthalmol. 259, 1821\u20131830. https:\/\/doi.org\/10.1007\/s00417-020-05028-5 (2021).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"32024_CR33","doi-asserted-by":"publisher","first-page":"9275","DOI":"10.1038\/s41598-021-88543-7","volume":"11","author":"DD Hwang","year":"2021","unstructured":"Hwang, D. D. et al. Distinguishing retinal angiomatous proliferation from polypoidal choroidal vasculopathy with a deep neural network based on optical coherence tomography. Sci. Rep. 11, 9275. https:\/\/doi.org\/10.1038\/s41598-021-88543-7 (2021).","journal-title":"Sci. Rep."},{"key":"32024_CR34","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1136\/bjophthalmol-2020-318559","volume":"106","author":"MJ Kim","year":"2022","unstructured":"Kim, M. J. et al. Novel utilisation of ultrawide-field fundus photography for detecting retinal nerve fibre layer defects in glaucomatous eyes. Br. J. Ophthalmol. 106, 1524\u20131529. https:\/\/doi.org\/10.1136\/bjophthalmol-2020-318559 (2022).","journal-title":"Br. J. Ophthalmol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32024-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32024-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32024-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T15:08:18Z","timestamp":1682348898000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32024-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,24]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["32024"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-32024-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,24]]},"assertion":[{"value":"22 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6685"}}